This study was the first to test the effect of two first-line therapies, i.e., the NO donor SNP and PDE5 inhibitor sildenafil, separately in the unaffected HP/HF and the affected HP/LF vasculatures. This evidence concerns the gene PDE5A and hydrops fetalis.